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Cell genesis and dendritic plasticity: a neuroplastic pas de deux in
the onset and remission from depression
A Mateus-Pinheiro1,2, P Patrı´cio1,2, JM Bessa1,2, N Sousa1,2 and L Pinto1,2
Brain neuroplasticity is increasingly considered to be an important component of both the pathology and treatment of depressive
spectrum disorders. Recent studies shed light on the relevance of hippocampal cell genesis and cortico-limbic dendritic plasticity
for the development and remission from depressive-like behavior. However, the neurobiological signiﬁcance of neuroplastic
phenomena in this context is still controversial. Here we summarize recent developments in this topic and propose an integrative
interpretation of data gathered so far.
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INTRODUCTION
The potential to respond to environmental stimuli through
dynamic rearrangements of synapto-dendritic networks, as well
as by regulating the generation of new neuronal and glial cells,
renders the brain highly mutable. These phenomena, collectively
known as neuroplasticity, are critical to promote neuronal
adaptations; its failure is now increasingly considered to be a
major component in many neuropsychiatric conditions. Among
these, depressive spectrum disorders are a paradigmatic example
of the importance of neuroplastic alterations in the adult brain.
Recent studies provide a comprehensive picture of the effects of
stress, a major trigger factor in depression, in the (de)regulation of
neuroplasticity;1–4 the latter is, in turn, related to the emergence
of physiological and behavioral alterations comprised in the
symptomatic proﬁle of depressive disorders. Although these
molecular and physiological mechanisms regulating neuroplastic
processes are relevant for the onset of depressive symptoms, they
have also been implicated in the action of antidepressants (ADs).
So far, and although there is still much to be elucidated, it is
becoming evident that the triad stress-neuroplasticity-depression
constitutes fertile ground for new ﬁndings.
NEW CELLS AND DENDRITES: IMPORTANCE FOR THE
TREATMENT AND REMISSION FROM DEPRESSION
Although different forms of neuroplasticity are affected in
depression, a debate endures concerning the exact neurobiolo-
gical signiﬁcance of postnatal hippocampal cell genesis, both for
the development of depressive pathology and for the therapeutic
action of ADs. From the bulk of evidence gathered so far, it is
increasingly appreciated that alterations in cell genesis are
involved in the pathology and treatment of depression; however,
there are several conﬂicting reports regarding its relevance. Three
factors are likely to contribute to these controversies. First, there is
a ‘necessary’ difﬁculty to approach this question in humans
suffering from depression; postmortem studies in humans and
animal models of depression have, nevertheless, provided
important insights. Second, it seems to exist a major prevalence
of studies focusing on the functional implications of neurogenesis,
in disregard of gliogenesis, a parallel cell-genesis process likely to
be of relevance in this context. Lastly, because these events are
highly dynamic, the adoption of different experimental models
and time frames when analyzing the participation of cell genesis
in the pathology and treatment of depression is critical to have a
complete perspective of the topic. On account of these
experimental dissimilarities, an integrative, and careful, interpreta-
tion of data published in the last years is required when
attempting to put the pieces of the puzzle together.
Suppression of hippocampal cell proliferation in naive animals
through irradiation, pharmacological approaches or through the
use of transgenic models of cytogenesis ablation has been shown
to be associated with the development of deﬁcits in different
behavioral dimensions commonly affected in depression.2,5,6
Strikingly, most of the studies in which analyses were performed
shortly after cytogenesis ablation did not reveal signiﬁcant
deﬁcits in most behavioral domains normally assessed in the
characterization of animal models of depression (Figure 1).7,8
However, recent reports in which abrogation of cytogenesis is
maintained for long periods (over 4 weeks)6 or in which the
behavioral analysis was conducted only 4 weeks after the
cessation of cytogenesis suppression,4 reported multidimen-
sional behavioral deﬁcits that emerged only weeks after the
antiproliferative insult. Importantly, the speciﬁc late manifestation
of depressive-like behavior and cognitive disabilities in animals in
which cytogenesis had been suppressed illustrates how mani-
pulating lengthy neuroplastic phenomena is associated with the
non-immediate development of behavioral impairments, which
are only fully manifested once newborn cells are expected to be
incorporated in local neuroglial circuits. This view has been
recently supported by the demonstration that the speciﬁc
inhibition of 4-week old new hippocampal neurons causes
deﬁcits in memory retrieval in mice; remarkably, inhibiting the
activity of either younger or less-plastic older neurons does not
produce effects in this cognitive domain.9
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Figure 1. The participation of dendritic plasticity and hippocampal cell genesis in the development and treatment of depression. (a) In animal
models of depression, chronic exposure to stress, one major trigger factor of depression, leads to the dendritic atrophy of hippocampal and
prefrontal cortex neurons and compromises the generation of new cells. These neuroplastic impairments are associated with the
development of multidimensional deficits manifested in behavioral dimensions such as mood, anxiety behavior and cognitive performance.
Treatment with typical SSRIs allows for the fast reestablishment of dendritic neuronal architecture, which is associated with the fast remission
from depression-like behavior. The slow generation of new neuronal and glial cells, potentiated by antidepressant (AD) treatment will be
fundamental to maintain this remission and to promote a sustained long-term recovery from depression. (b) Suppression of hippocampal cell
genesis, using X-ray irradiation, the cytostatic agent methylazoxymethanol or transgenic animal models of cytogenesis ablation, does not
seem to have an impact on the mood-improving effects of ADs, but rather to preclude AD’s efficacy in reversing anxiety behavior and
impairments in some cognitive modalities (blue line); other cognitive functions remain unaffected (dashed blue line). (c) Ablation of
cytogenesis in naive animals, while maintaining dendritic morphology intact, leads to the short-term manifestation of hyperanxiety behavior;
deficits in mood and cognitive modalities are only evident later on, when newborn cells are expected to be fully matured and incorporated in
the local neurocircuitry. SSRIs, selective serotonin reuptake inhibitors.
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An exception must be made in respect to anxiety behavior,
because disruption of hippocampal cytogenesis is associated to
the immediate development of heightened anxiety, which is
commonly comorbid in depressed patients. In fact, it has been
demonstrated that immature newborn neurons display a major
role in anxiety behavior control.10–12
In contrast with the slow reconﬁguration of neuroglial networks
promoted by the addition of new cells in the adult brain, are the
rapid synaptic and dendritic morphological changes. These
underlie the short-term impacts on distinct emotional and
cognitive processes observed in the onset of depressive
symptoms. Indeed, defects on neuronal cytoarchitecture have
been documented in postmortem analysis of brain tissue from
depressive patients, which seem to be ameliorated by chronic AD
treatment.13,14 These structural defects include cortico-limbic
dendritic atrophy in depressed subjects,15 accompanied by
abnormalities in glial cell structure. Importantly, in animal
models of depression, these changes are associated with
hallmarks of depressive behavior, such as anhedonic behavior,
behavioral despair and cognitive disabilities.2
Besides this common participation of slow cytogenesis pro-
cesses and rapid dendritic rearrangements in the pathology of
depressive spectrum disorders, these two neuroplastic phenom-
ena, with very different temporal dynamics, constitute the
substrate by which ADs (partially) exert their therapeutic actions.
Thus, the reestablishment of normal neuroglial networks seems to
be achieved in a biphasic manner (Figure 1): in a short-term
context, AD actions rely on rapid modulatory effects upon genes
involved in the restructuring of the synaptic network; later on, the
generation of new fully matured neuronal and glial cells will have
an impact on the long-term remission from emotional and
cognitive disabilities manifested during a depressive episode. In
fact, despite triggering an immediate pro-proliferative response,
this early effect corresponds only to the onset of a slow
neuroadaptation whose neurobiological importance can only be
fully appreciated later on, once new cells attain complete
maturation and functionality, and are integrated in the local
neurocircuitry. Taken together, and because mammalian neuro-
genesis is described to take 4–6 weeks, the overall outcome of AD’s
therapeutic action upon neuroplasticity may only be entirely
manifested after this period. Remarkably, this period correlates
with the time latency that typically prescribed ADs take to fully
manifest their action in depressive patients.
Although the neuroplastic alterations occurring during the onset,
treatment and remission from depression are being increasingly
characterized, comprehension of the processes (namely genetic
and epigenetic programs) that orchestrate these alterations is still
limited. Future research focusing on these processes should also be
extended to the still underexplored glioplastic component of this
disorder. Furthermore, local neuroplastic adaptations are likely to
occur in articulation with systemic neuroendocrine and immuno-
logical alterations, which are still to be integrated in the complex
puzzle of mechanisms implicated in depression.
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